MedTrace Logo

Myocardial Ischaemia After Exposure to Diesel Exhaust

NCT01661582 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-05-09

No results posted yet for this study

Summary

Exposure to particulate air pollution is associated with increases in cardiovascular mortality and morbidity. The pathophysiological mechanisms underlying this observation are emerging, and exposure to particulate air pollution has been shown to result in increases in blood pressure and arterial tone, impaired vascular function and an increased tendency for blood to clot as well as an increase in atherosclerotic plaque burden. Recent evidence from panel studies and controlled exposure studies have suggested an increase in myocardial ischaemia (a reduction in blood flow to the heart) following exposure. In this study we aim to investigate directly myocardial (heart) blood flow following exposure to diesel exhaust (as a model of urban air pollution) using CT/PET myocardial perfusion imaging in male patients with stable coronary disease and healthy male controls. We hypothesize that following exposure to dilute diesel exhaust:

1. Myocardial blood flow will be reduced
2. Coronary flow reserve will be impaired
3. The magnitude of impairment will be higher in patients with coronary disease as compared to healthy controls

Conditions

Interventions

OTHER

CT/PET Myocardial Perfusion Imaging using O-15 water

OTHER

Coronary blood flow measured by doppler echocardiography

Sponsors & Collaborators

  • National Institute for Public Health and the Environment (RIVM)

    collaborator OTHER_GOV

  • British Heart Foundation

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • David E Newby, PhD FRCP · University of Edinburgh

  • Jeremy P Langrish, MB BCh MRCP · University of Edinburgh

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-20
Primary Completion
2015-02-13
Completion
2015-02-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01661582 on ClinicalTrials.gov